Nathaniel Jacobson
FSA, MAAA
Senior Consulting Actuary
New York, NY, US
Nathaniel Jacobson is a senior consulting actuary with extensive experience working directly with providers participating in alternative payment models and value-based care arrangements. Nathaniel works closely with ACOs (MSSPs, REACH ACOs, Medicaid ACOs, and others) to project and monitor financial performance, identify opportunities, and model the impact of changes to programs.
Experience
Nathaniel's experience as an actuary includes:
- ACO participation support and modeling
- Value-based care models
- Risk score modeling
- Capitation payment analysis
Professional Designations
- Fellow, Society of Actuaries
- Member, American Academy of Actuaries
Education
- BA, Mathematics and Philosophy, Cornell University - Ithaca, New York
Publications
Read their latest work
Article
ACO REACH PY2026 explained: What is changing and why it matters
17 June 2025 - by Tabish Shaikh, Chris Smith, Emma Kramer, Noah Champagne, Nathaniel Jacobson
We put the Center for Medicare and Medicaid Innovation's 2026 updates to the ACO REACH program into context.
Article
Why voluntary alignment may not meet your ACO’s expectations
10 November 2022 - by Charlie Mills, Nathaniel Jacobson, Noah Champagne
We explore the voluntary alignment requirements for global/professional direct contracting and ACO REACH, along with considerations for beneficiary engagement.
Article
Health coverage in the Gig Economy – Experience from several countries
02 February 2022 - by Somya Bansal, Joanne Buckle, Diana Dodu, Nathaniel Jacobson, Alexander Krauskopf, Monika Lis, Yunzi Xia, Rong Yi
Health insurance companies must adapt and innovate their product offerings to appeal to the expectations of freelancers and on-demand gig workers.
Article
The role of pharmacy benefits on ACA market premiums: Decomposing premium trends in the individual and small group markets
27 October 2020 - by Dane Hansen, Gabriela Dieguez, Nathaniel Jacobson, Emily DeAngelis
This paper examines the role of prescription drug costs in premium increases in the Patient Protection and Affordable Care Act individual and small group marketplaces.
Article
Site of Service and Cost Dispersion of Infused Drugs
11 December 2019 - by Gabriela Dieguez, Tyler Engel, Nathaniel Jacobson
This paper examines the cost dispersion of one infused disease-modifying therapies treatment, ocrelizumab, by site of service for patients with commercial insurance, a major insurance segment for multiple sclerosis patients.